Oriola-KD Corporation Stock Exchange Release 29 July 2010 at 8.30 a.m.

Oriola-KD Corporation’s Interim Report for 1 January – 30 June 2010

This review presents financial information regarding the continuing operations of
Oriola-KD Group (hereinafter Oriola-KD) for the period January-June 2010. Oriola-KD’s
Healthcare Trade business was sold on 31 May 2010 and its figures are reported in the
tables in the discontinued operations section. The interim report 1 January-30 June 2010
was drawn up in accordance with the IAS 34 standard and Oriola-KD’s 2009 annual report.
In addition, new IAS/IFRS standards have been adopted in 2010, the most important of
which are IFRS 3 and IAS 27. The figures are unaudited.

Oriola-KD sold its Healthcare Trade business to Mediq N.V. on 31 May 2010 for approx.
EUR 85 million. A profit of EUR 54.0 million was entered for the corporate transaction
and as a consequence the Group’s goodwill decreased by EUR 7.7 million during the second
quarter of 2010. The final value of the deal and the profit entered will be specified
according to the conditions associated with the acquisition price by the end of 2010.

Key figures for continuing operations for 1 January – 30 June 2010

*
The figures refer to continuing operations and do not include the Healthcare Trade,
unless otherwise stated

*
Net sales increased 21 per cent to EUR 903.1 million (Jan-Jun 2009: EUR 746.5 million)

*
Operating profit decreased 47 per cent to EUR 11.3 million (Jan-Jun 2009: EUR 21.2
million)

*
Net profit decreased 52 per cent to EUR 7.4 million (Jan-Jun 2009: EUR 15.3 million)

*
Earnings per share were EUR 0.05 (Jan-Jun 2009: EUR 0.11)

*
Net cash flow from operations including the cash flow from the Healthcare Trade business
was EUR 54.1 million (Jan-Jun 2009: EUR -5.8 million)

*
Return on capital employed was 4.8 per cent (Jan-Jun 2009: 16.1 per cent including the
Healthcare Trade transaction)

*
Oriola-KD’s net sales from its continuing operations for 2010 is forecasted to be higher
than in 2009 and operating profit is forecasted to be lower than in 2009

Key figures for continuing operations for 1 April – 30 June 2010

*
The figures refer to continuing operations and do not include the Healthcare Trade,
unless otherwise stated

*
Net sales increased 29 per cent to EUR 487.3 million (Q2/2009: EUR 377.8 million)

*
Operating profit decreased 20 per cent to EUR 8.4 million (Q2/2009: EUR 10.5 million)

*
Net profit decreased 29 per cent to EUR 5.4 million (Q2/2009: EUR 7.6 million)

*
Earnings per share were EUR 0.04 (Q2/2009: EUR 0.05)

President and CEO Eero Hautaniemi: “The net sales of Oriola-KD’s continuing operations
increased 21 per cent to EUR 903 million and operating profit decreased 47 per cent to
EUR 11 million in January-June 2010. Businesses developed according to our expectations
in the second quarter. We took over the pharmacy chain acquired in Sweden and continued
to expand and intensify operations in Russia in a very difficult market situation. We
sold our Healthcare Trade business to Dutch company Mediq with EUR 85 million in May
2010.”

Financial performance

The figures related to financial performance refer to continuing operations and do not
include the Healthcare Trade, unless otherwise stated.

Oriola-KD’s net sales in January-June 2010 were EUR 903.1 million (EUR 746.5 million)
and operating profit was EUR 11.3 million (EUR 21.2 million). Profit after financial
items came to EUR 9.0 million (EUR 19.4 million) and net profit to EUR 7.4 million (EUR
15.3 million). Earnings per share in January-June 2010 were EUR 0.05 (EUR 0.11).

Second-quarter net sales came to EUR 487.3 million (EUR 377.8 million) and operating
profit to EUR 8.4 million (EUR 10.5 million). Profit after financial items came to EUR
6.9 million (EUR 9.5 million) and net profit to EUR 5.4 million (EUR 7.6 million).
Earnings per share in the second quarter were EUR 0.04 (EUR 0.05).

Oriola-KD’s financing expenses in January-June 2010 were EUR 2.3 million (EUR 1.8
million). Taxes amounted to EUR 1.6 million (EUR 4.1 million). Taxes corresponding to
the result for continuing operations for the January-June 2010 period are entered under
this figure.

Return on capital employed for continuing operations was 4.8 per cent (16.1 per cent
including the Healthcare Trade) and return on equity 5.1 per cent (19.1 per cent
including the Healthcare Trade) in January-June 2010.

Net sales generated by the discontinued Healthcare Trade business came to EUR 65.3
million and operating profit to EUR 2.9 million in January-May 2010. The business had
approximately 440 employees in Finland, Sweden, Denmark, Estonia, Latvia and Lithuania.

Balance sheet, financing and cash flow

The figures related to the balance sheet, financing and cash flow include the figures
for the Healthcare Trade until 31 May 2010 and the operating profit from the
transaction. The Swedish pharmaceutical retail business is included in Oriola-KD’s
figures as of 19 February 2010. The Healthcare Trade business was sold on 31 May 2010.

Oriola-KD’s balance sheet total on 30 June 2010 stood at EUR 1173.2 million (EUR 819.2
million). Cash and cash equivalents on 30 June 2010 stood at EUR 148.1 million (EUR 42.2
million). Equity was EUR 325.9 million (EUR 205.5 million) and the equity ratio was 28.5
per cent (25.8 per cent). The sale of the Healthcare Trade increased Oriola-KD’s equity
and equity ratio and decreased interest-bearing net debt and goodwill.

Interest-bearing net debt at the end of June 2010 was EUR 75.1 million (EUR 101.1
million) and the gearing ratio was 23.0 per cent (49.2 per cent). Oriola-KD hedged the
long-term interest-bearing debt associated with the Swedish pharmaceutical retail trade
against interest rate risk during the second quarter of 2010. Interest-bearing net debt
consists of long-term debt financing, use of the issued commercial paper programme,
advance payments from pharmacies and the estimated discounted value of the minority
share of the Swedish pharmacy company that Oriola-KD is obliged to acquire.

The terms of the financial covenants were met with a wide margin at the end of June
2010. Oriola-KD’s long-term credit limit facilities of approximately EUR 101.5 million
and EUR 41.0 million in short-term credit account facilities stood unused at the end of
the review period. Oriola-KD had drawn EUR 78.9 million from the EUR 150.0 commercial
paper programme.

Net cash flow from operations in January-June 2010 was EUR 54.1 million (EUR -5.8
million), of which changes in working capital accounted for EUR 33.6 million (EUR -24.6
million). The trade receivables sales programme of the Swedish pharmaceutical wholesale
was continued during the second quarter of 2010.

Net cash flow from investments was EUR -153.3 million (EUR -26.7 million). Net cash flow
from investments includes the acquisition of pharmacy chain in Sweden, the acquisition
of the 25 per cent minority share in Russia, operative investments and the sale of the
Healthcare Trade. During the January-June 2010 period, cash flow after investments was
EUR -99.2 million (EUR -32.5 million).

On 24 February 2010, Oriola-KD acquired the remaining 25 per cent holding in Foreti Oy,
which owns the pharmaceutical retail company (OOO Vitim) and pharmaceutical wholesale
company (OOO Moron) operating in Russia. As a result of the acquisition, Oriola-KD’s
Russian subsidiaries are now fully-owned. The price of the 25 per cent holding was EUR
65.0 million. The total price of the corporate acquisition in Russia was EUR 153.7
million, paid in cash.

Oriola-KD paid EUR 18.1 million in dividends for 2009, i.e. EUR 0.12 per share (EUR 0.08
per share in 2008) during the second quarter.

Investments

Gross investments in January-June came to EUR 185.7 million (EUR 24.0 million) including
the acquisition of the pharmacy chain in Sweden and operative investments. In addition
the Healthcare Trade business was sold with EUR 85 million in the review period.

On 19 February 2010, Kronans Droghandel Retail AB acquired 100 per cent of the stock of
a pharmacy company with 170 pharmacies nationwide. Paid in cash, the price was EUR 161.5
million (SEK 1.59 billion). Oriola-KD has an 80 per cent holding in Kronans Droghandel
Retail AB and the remaining 20 per cent is held by KF (Kooperativa Förbundet). Oriola-KD
has an obligation and right to acquire a minority share in Kooperativa Förbundet after
long-term cooperation. The obligation to acquire was entered under long-term
interest-bearing debt in the Oriola-KD balance sheet in conjunction with the acquisition
of the pharmacies. Kronans Droghandel Retail AB is 100 per cent consolidated into
Oriola-KD’s income statement and balance sheet.

Personnel

The figures related to personnel refer to the continuing operations, not including the
Healthcare Trade.

On 30 June 2010, Oriola-KD had a payroll of 4,721 (3,925) employees, 11 per cent (11 per
cent) of whom worked in Finland, 29 per cent (7 per cent) in Sweden, 58 per cent (79 per
cent) in Russia and 2 per cent (3 per cent) in the Baltic countries. The numbers
increased because of the acquisition of the Swedish pharmacy chain in February 2010,
which added some 930 persons.

Changes to the Oriola-KD Group Management Team: Ilari Vaalavirta who was a member of the
Group Management Team and Vice President of the Healthcare Trade transferred to Mediq
with the sale of the Healthcare Trade during the second quarter of 2010.

Business segments

In accordance with its organisational structure and internal reporting, Oriola-KD’s
business segments after the sale of Healthcare Trade are, as of 1 June 2010,
Pharmaceutical Trade Finland, Pharmaceutical Trade Sweden, Pharmaceutical Trade Russia,
Pharmaceutical Trade Baltic Countries and Dental Trade.

Pharmaceutical Trade Finland

Pharmaceutical Trade Finland’s net sales in January-June 2010 were EUR 210.4 million
(EUR 258.8 million) and its operating profit was EUR 9.5 million (EUR 8.8 million).
During the review period, changes from the stock owned by Oriola-KD to consignment
stock, agreed with pharmaceutical companies, reduced net sales.

Net sales in the second quarter of 2010 were EUR 105.9 million (EUR 132.0 million) and
operating profit EUR 5.0 million (EUR 4.9 million).

The pharmaceutical market declined by 1.4 percent (grew 0.2%) in Finland in January-June
2010. Oriola-KD’s market share in the Finnish pharmaceutical wholesale market was 46.4
per cent (46.8 per cent) in January-June 2010 (source: IMS Health). No major changes in
principals that would have had a bearing on market share took place in the review
period.

Pharmaceutical Trade Finland had 492 (405) employees at the end of June 2010.
Oriola-KD’s logistics centres are located in Espoo and Oulu. The increase of personnel
is mainly due to recruitments to replace leased work force, labour intensive new
products and the provision of certain transitional services in relation to the
divestment of the Healthcare Trade.

Pharmaceutical Trade Sweden

Pharmaceutical Trade Sweden’s net sales in January-June 2010 were EUR 422.4 million (EUR
256.9 million), of which retail accounted for EUR 166.3 million (EUR 0.0 million) as of
19 February 2010 and wholesale EUR 276.5 million (EUR 256.9 million). The retail
business acquired has been consolidated with the Oriola-KD figures as of 19 February
2010.

Pharmaceutical Trade Sweden’s operating profit in January-June 2010 was EUR 4.2 million
(EUR -2.3 million). The costs associated with the preparations concerning the pharmacy
business in Sweden in 1 January 2010 – 19 February 2010 were EUR 2.2 million (EUR 6.0
million in January-June 2009). In addition, EUR 0.7 million has been entered as
depreciation on the fair value allocation of the acquisition.

Second-quarter net sales came to EUR 241.4 million (EUR 130.5 million), of which retail
accounted for EUR 115.5 million (EUR 0.0 million) and wholesale EUR 140.3 million (EUR
130.5 million). Operating profit was EUR 5.6 million (EUR -2.0 million).

On 19 February 2010, Kronans Droghandel Retail AB acquired 100 per cent of the stock of
a pharmacy company with 170 pharmacies nationwide. Paid in cash, the final price was EUR
161.5 million (SEK 1.59 billion). In 2009, the pro forma net sales of the acquired
pharmacy cluster was SEK 4.6 billion (SEK 4.4 billion in 2008) and pro forma operating
profit including average central overhead costs of Apoteket AB was SEK 205 million (SEK
183 million in 2008). Oriola-KD had 173 pharmacies in Sweden at the end of June 2010.
Oriola-KD’s logistics centres are located in Gothenburg and Enköping.

The pharmaceutical market grew 0.6 per cent (2.8 per cent) in Sweden in January-June
2010. Oriola-KD’s market share in the Swedish wholesale market was 40.4 per cent (41.4
per cent) in January-June 2010 (source: IMS Health).

Pharmaceutical Trade Sweden had 1360 (268) employees at the end of June 2010, of whom
1045 (0) were employed in retail and 315 (268) in wholesale.

Pharmaceutical Trade Russia

Pharmaceutical Trade Russia’s net sales in January-June 2010 were EUR 255.0 million (EUR
213.9 million), of which retail accounted for EUR 47.5 million (EUR 49.7 million) and
wholesale EUR 231.9 million (EUR 192.3 million).

The January-June 2010 operating loss was EUR 2.5 million (operating profit of EUR 16.3
million), which includes discounts from pharmaceutical companies associated with
purchases. The Russian pharmaceutical market growth in Russian rubles was some 0 per
cent in January-June 2010 (some 30 per cent), which together with the price control
system has led to very intense competition. Oriola-KD’s net sales increased by about 8
per cent (35 per cent) in Russian rubles in January-June 2010.

Second-quarter net sales came to EUR 132.8 million (EUR 106.6 million), of which retail
accounted for EUR 23.9 million (EUR 24.0 million) and wholesale EUR 121.3 million (EUR
95.9 million). Operating loss was EUR 2.0 million (operating profit of EUR 8.6 million).

At the end of June 2010, Oriola-KD had 181 (163) pharmacies in the Moscow region and
nine regional distribution centres in Russia in addition to its main logistics centre.
Also, Oriola-KD started pharmaceutical wholesale in Yekaterinburg and Novosibirsk during
the first half-year. The regional expansion of the Russian wholesale business and the
growth of the retail business in Moscow will be continued during 2010.

Pharmaceutical Trade Russia had 2,766 (3,119) employees at the end of June 2010, of whom
1,277 (1,609) were employed in retail and 1,489 (1,510) in wholesale. Measures were
taken to improve the efficiency of operations, and as a consequence the number of
employees has decreased in spite of the increase in the number of pharmacies and the
regional expansion of the wholesale business.

Pharmaceutical Trade Baltic Countries

Pharmaceutical Trade Baltic Countries’ net sales in January-June 2010 were EUR 15.6
million (EUR 17.3 million) and operating profit was EUR 0.4 million (EUR 0.4 million).

Second-quarter net sales were EUR 7.3 million (EUR 8.8 million) and operating profit EUR
0.2 million (EUR 0.2 million).

Oriola-KD discontinued pharmaceutical wholesale in Estonia in the first quarter of 2010.
The discontinuation of business operations did not have any material cost effect.

Pharmaceutical Trade Baltic Countries had 103 (133) employees at the end of June 2010.

Dental Trade

In January-June 2010, the operating profit of Dental Trade was EUR 3.1 million (EUR 1.8
million). Second-quarter operating profit was EUR 1.4 million (EUR 0.7 million).

The dental trade businesses of Oriola-KD Corporation and Lifco AB were combined in 2007.
Oriola-KD’s holding in the Dental Trade business is 30 per cent and Lifco’s holding is
70 per cent. Oriola-KD’s operating profit includes the profit after taxes from the
associated company.

Related parties

Related parties in the Oriola-KD Group are deemed to comprise the parent company
Oriola-KD Corporation, the subsidiaries and associated companies, the members of the
Board and the President and CEO of Oriola-KD Corporation, other members of the Group
Management Team of the Oriola-KD Group, the immediate family of the aforementioned
persons, the companies controlled by the aforementioned persons, and the Oriola Pension
Foundation. The Group has no significant business transactions with related parties,
except for pension expenses arising from defined benefit plans with the Oriola Pension
Foundation. Oriola-KD Corporation has given internal loans mainly to the holding
companies of Swedish and Russian businesses. Oriola-KD Corporation has given no
significant sureties on behalf of Group companies, with the exception of a mother
company guarantee for a loan given to Kronans Droghandel Retail AB.

Oriola-KD Corporation shares

Trading volume of Oriola-KD Corporation’s class A and B shares in January-June 2010:

Trading volume Jan-Jun 2010 Jan-Jun 2009
Class A Class B Class A Class B
Trading volume, million 3.6 53.8 2.9 42.2
Trading volume, EUR million 16.9 228.4 6.3 95.9
Highest, EUR 5.47 5.49 2.85 2.85
Lowest, EUR 3.30 3.30 1.68 1.68
Closing quotation, end of period, EUR 3.95 3.83 2.77 2.76

3.83

2.77

2.76

In the review period, the traded volume of Oriola-KD Corporation shares, excluding
treasury shares, corresponded to 38.0 per cent (31.6 per cent) of the total number of
shares. The traded volume of class A shares amounted to 7.5 per cent (6.0 per cent) of
the average stock, and that of class B shares, excluding treasury shares, 52.1 per cent
(44.8 per cent).

Oriola-KD Corporation’s market capitalisation on 30 June 2010 was EUR 585.0 million (EUR
417.0 million).

On 8 March 2010, pursuant to the authorisation granted to it by the Annual General
Meeting of 13 March 2007, the Board of Directors of Oriola-KD Corporation resolved that
a directed bonus issue be made, in which a total of 209,300 class B shares held by the
company were assigned to the company’s President and CEO and to certain other members of
Oriola-KD Corporation’s Group Management Team and of its extended Group Management Team,
as part of the 2007-2009 share-based incentive scheme for the Group’s management. These
shares represent approximately 0.14 per cent of the total number of company shares and
approximately 0.02 per cent of the total number of votes.

On 28 June 2010, pursuant to the authorisation granted to it by the Annual General
Meeting of 13 March 2007, the Board of Directors of Oriola-KD Corporation resolved that
a directed bonus issue be made, in which a total of 37,350 class B shares held by the
company were assigned to certain key members of the Oriola-KD Group as part of the
2007-2009 share-based incentive scheme for the Group’s management. These shares
represent approximately 0.02 per cent of the total number of company shares and
approximately 0.0035 per cent of the total number of votes.

The company has 96,822 treasury shares, all of which are class B shares. These account
for 0.06 per cent of the company’s shares and 0.009 per cent of the votes.

At the end of June 2010, the company had 151,257,828 shares (151,257,828), of which
47,217,359 were class A shares (48,392,203) and 104,040,469 were class B shares
(102,865,625). Pursuant to article 3 of the Articles of Association, a shareholder can
request that class A shares be converted to class B shares. During January-June 2010, a
total of 450,000 (300,000) Class A shares were converted into Class B shares

The Board of Directors of Oriola-KD has defined the earning criteria for the share
incentive scheme for the Group’s key personnel for the years 2010-2012 so that any
payment for the 2010 earning period will be based on Oriola-KD’s earnings per share
(EPS) and return on capital employed (ROCE).

Risks

The Board of Directors of Oriola-KD has approved the company’s risk management policy in
which the risk management operating model, principles, responsibilities and reporting
are specified. The Group’s risk management seeks to identify, measure and manage risks
that may threaten the operations of the company and the achievement of goals set for
them. The roles and responsibilities relating to risk management have been determined in
the Group.

Oriola-KD’s risks are classified as strategic, operational and financial. Risk
management is a key element of the strategic process, operational planning and daily
decision-making at Oriola-KD.

Oriola-KD has identified the following principal strategic and operational risks in its
business:

*
changes in bargaining position vis-à-vis suppliers and customers;

*
impacts of the changes in Pharmaceutical Trade Sweden on business;

*
impacts of the changes in Pharmaceutical Trade Russia on business;

*
maintenance of cost-effectiveness and flexibility in costs;

*
provision of competitive products and services in expanding and consolidating markets;
and

*
commitment of key employees.

The major financial risks for Oriola-KD involve currency exchange rates, interest rates,
liquidity and credit.

Oriola-KD’s exposure to risks relating to businesses and financial risks has increased
with the expansion into the Russian pharmaceutical retail and wholesale market and the
Swedish pharmaceutical retail market. Currency risks are the most significant of
Oriola-KD’s financial risks in Russia and Sweden, as any changes in the value of the
Russian ruble or the Swedish krona will have an impact on Oriola-KD’s financial
performance and equity.

Goodwill and intangible rights are subject to annual impairment testing, which may have
a negative effect on Oriola-KD’s financial performance.

Near-term risks and uncertainty factors

The difficult state of the Russian economy, intense competition and the price control
system have a material impact on Oriola-KD near-term outlook in the country. The
development of the Swedish pharmacy market is subject to uncertainties that may have a
substantial effect on Oriola-KD’s Swedish business.

Decisions of the Annual General Meeting

The Annual General Meeting of Oriola-KD Corporation, held on 7 April 2010, confirmed the
2009 financial statements and discharged the Board members and the President and CEO
from liability for the financial year ending 31 December 2009. The Annual General
Meeting resolved that the sum of EUR 0.12 per share be paid as dividend on the basis of
the balance sheet adopted for the financial year ending 31 December 2009.

The Board was authorised, in accordance with its proposal, to decide on the payment of
additional dividend from undistributed profits and/or distribution of funds, in one or
more batches, from the company’s invested non-restricted equity fund or both so that the
amount of the additional dividend and/or return of capital paid under the authorisation
would not exceed EUR 0.05 per share. The authorisation will be in force until the next
annual general meeting.

The Annual General Meeting confirmed that the Board comprises eight members. Harry
Brade, Pauli Kulvik, Outi Raitasuo, Antti Remes, Olli Riikkala, Jaakko Uotila and Mika
Vidgrén were re-elected to the Board. Per Båtelson was elected as a new member to the
Board. Olli Riikkala continues as Chairman of the Board. The Annual General Meeting
confirmed that the Chairman of the Board will receive EUR 48,400 in remuneration for his
term of office, the Vice Chairman EUR 30,250 and the other members of the Board EUR
24,200 each. Of the annual fees, 60 per cent will be paid in cash and 40 per cent in
company shares so that after the release of the company’s interim report for the first
quarter of 2010, Oriola-KD Corporation Class B shares would be acquired on the market
for Board members, and the cash portion of the annual fee will also be paid. The
Chairman of the Board will receive an attendance fee of EUR 800 for each meeting, and
the other Board members EUR 400 per meeting. Meeting fees will also be paid in the same
manner to members of any committees set up by the Board of Directors or the company. The
Chairman of the Board will also have a company-paid phone. Travel expenses will be paid
in accordance with the travel policy of the company.

The Annual General Meeting re-elected PricewaterhouseCoopers Oy as auditor for the
company, with Heikki Lassila APA as principal auditor, for the 2010 financial year. The
auditor will be remunerated according to invoice.

The Annual General Meeting resolved that article 12 of the Articles of Association on
time of the notice of general meeting be amended.

The Annual General Meeting authorised the Board to decide on the purchase of Oriola-KD
Corporation class B shares in accordance with the Board’s proposal. Pursuant to the
authorisation, the Board is authorised to decide on the purchase of no more than
15,000,000 of the company’s own class B shares, corresponding to approximately 9.92 per
cent of the total number of company shares. The authorisation can only be used in such a
way that the company and its subsidiaries together would hold no more than one tenth
(1/10) of the total number of company shares at any one time. The purchase authorisation
would remain in force no longer than eighteen (18) months following the decision of the
General Meeting. The authorisation revokes the Annual General Meeting’s decision of 16
April 2009 authorising the Board to decide on the purchase of Oriola-KD Corporation
class B shares.

The Annual General Meeting authorised the Board to decide on a share issue of the
company’s shares against payment in one or more batches in accordance with the Board’s
proposal. The authorisation includes the right to issue new class B shares or to assign
class B shares held by the company. The authorisation covers no more than thirty million
(30,000,000) of the company’s class B shares in total, which corresponds to
approximately 19.83 per cent of the total number of company shares. The authorisation
granted to the Board includes the right to deviate from the pre-emptive subscription
right of shareholders, provided that there are financial grounds considered important
from the company’s perspective for such a deviation. The authorisation will remain in
force for eighteen (18) months following the decision of the General Meeting. The
authorisation revokes the share issue authorisations previously received by the Board,
with the exception of the authorisation granted to the Board by the Annual General
Meeting of 13 March 2007, under which the Board may decide on arranging a directed bonus
issue of no more than 650,000 class B shares for the purpose of implementing the
2007-2009 share-based incentive scheme for management.

The Annual General Meeting also authorised the Board to decide on granting the company’s
shares to the company in one or more batches under a bonus issue in accordance with the
Board’s proposal. The maximum amount of the company’s new B class shares issued under
this authorisation is 1,200,000, which was 0.79 per cent of the company’s total shares
and 0.11 per cent of total votes. The purpose of the authorisation is to allow treasury
shares to be used as laid out below in the new share-based incentive scheme or Oriola-KD
key persons. The Board was also authorised to issue class B shares, waiving the
pre-emptive subscription rights of the shareholders according to the Board’s proposal.
The class B shares issued may be either new or treasury shares. The total share amount
of the authorisation is 1.200.000 class B shares. The share issue may be a bonus issue.
These shares represent approximately 0.79 per cent of the total number of company shares
and approximately 0.11 per cent of the total number of votes. The Board may use this
authorisation in the new 2010-2012 share-based incentive scheme or Oriola-KD key
persons. The authorisations remain in force for no more than four (4) years following
the decision of the General Meeting.

Decisions of the organisational meeting of the Board

At the organisational meeting held immediately after the AGM, the Board resolved to
elect Antti Remes to continue serving as Vice Chairman of the Board. The composition of
the Audit and Compensation Committees was confirmed as follows.

Audit Committee:
Antti Remes, Chairman
Harry Brade
Outi Raitasuo
Mika Vidgrén

Compensation Committee:
Olli Riikkala, Chairman
Pauli Kulvik
Jaakko Uotila

The company also has a Nomination Committee, the members of which will be elected later.

The Board of Directors has evaluated the independence of its members and found that all
the members are independent of both the company and its major shareholders.

Outlook

Oriola-KD’s outlook for 2010 is based on external market forecasts, agreements with
suppliers and customers, order intake and management assessments. Long-term fundamentals
and growth prospects are expected to be favourable in the pharmaceutical market.

Oriola-KD expects that the pharmaceutical market in Finland and Sweden will grow by
about 3-5 per cent annually over the next few years in the local currencies, which is in
line with the longer-term average growth rate of these markets. The Russian
pharmaceutical market is expected to see annual growth of approximately 10-15 per cent
in Russian rubles in the next few years. The growth of the Russian pharmaceutical market
in 2010 is expected to be significantly slower than in the long term, mainly because of
the difficult state of the Russian economy, very intense competition and the price
control system. Competition in the Swedish retail market is expected to be stiff in 2010
as a result of the deregulation.

Oriola-KD’s net sales from its continuing operations for 2010 is forecasted to be higher
than in 2009 and operating profit is forecasted to be lower than in 2009. Pharmaceutical
Trade Russia’s operating profit is forecasted to be clearly lower than in 2009.

Tables

Consolidated Statement of 1 Jan – 30 June 1 Jan – 30 June 1 Apr – 30 June 1 Apr – 30 June 1 Jan – 31 Dec
Comprehensive Income (IFRS), 2010 2009 2010 2009 2009
EUR million
Continuing operations
Net sales 903.1 746.5 487.3 377.8 1569.2
Cost of goods sold -779.9 -649.2 -416.7 -330.0 -1363.8
Gross profit 123.2 97.4 70.6 47.7 205.4
Other operating income 1.9 1.0 0.8 0.5 2.1
Selling and
distribution expenses -91.2 -63.2 -45.5 -32.3 -129.2
Administrative expenses -25.7 -15.7 -19.0 -6.2 -25.8
Profit from
associated companies 3.1 1.8 1.4 0.8 3.9
Operating profit 11.3 21.2 8.4 10.5 56.4
Financial income 3.4 4.6 2.3 2.6 7.9
Financial expenses -5.7 -6.4 -3.8 -3.5 -9.9
Profit before taxes 9.0 19.4 6.9 9.5 54.5
Income taxes*) -1.6 -4.1 -1.5 -1.9 -11.4
Profit from the continuing operations
for the period under review 7.4 15.3 5.4 7.6 43.0

Discontinued operations
Profit from the discontinued operations
for the period under review 56.2 3.4 55.3 2.2 5.6
Profit for the period under review
including discontinued operations 63.6 18.7 60.7 9.8 48.6

Other comprehensive income
Hedge of a net investment in a
foreign operation 8.2 -2.7 2.5 1.2 -2.0
Cash flow hedge -0.4 – -0.4 – –
Income tax relating to other comprehensive income -1.6 0.5 -0.5 -0.2 0.4
Translation difference 30.8 -4.9 17.1 3.2 1.3
Total comprehensive income for the period under review
including discontinued operations 100.6 11.7 79.4 13.9 48.4

Attribution of profit from the continuing operations
for the period under review
To parent company shareholders 7.4 15.3 5.4 7.6 43.9
To minority interest – – – – -0.9

Attribution of profit for the period under review
including discontinued operations
To parent company shareholders 63.6 18.7 60.7 9.8 49.5
To minority interest – – – – -0.9

Attribution of total comprehensive income for the
period under review (including discontinued operations)
To parent company shareholders 100.6 11.7 79.4 13.9 49.3
To minority interest – – – – -0.9

Earnings per share
from the continuing operations
Basic earnings per share, EUR 0.05 0.11 0.04 0.05 0.30
Diluted earnings per share, EUR 0.05 0.11 0.04 0.05 0.30

Earnings per share
for the period under review
(including discontinued operations)
Basic earnings per share, EUR 0.42 0.13 0.40 0.07 0.34
Diluted earnings per share, EUR 0.42 0.13 0.40 0.07 0.34

*) The tax expense for the period has been calculated as the proportional share of the
total estimated taxes for the financial year.

Consolidated Balance Sheet (IFRS),
EUR million

ASSETS 30 June 2010 30 June 2009 31 Dec
2009

Non-current assets
Property, plant and equipment 61.0 53.1 53.3
Goodwill 258.4 118.9 141.7
Other intangible assets 72.6 38.7 39.5
Investments in associated companies 30.4 28.4 30.7
Other non-current assets 8.3 8.7 7.5
Deferred tax assets 5.7 2.3 2.5
Non-current assets total 436.5 250.1 275.2

Current assets
Inventories 311.8 261.1 287.1
Trade and other receivables 276.8 265.8 227.1
Cash and cash equivalents 148.1 42.2 133.7
Current assets total 736.7 569.1 647.8

ASSETS TOTAL 1173.2 819.2 923.1

EQUITY AND LIABILITIES 30 June 2010 30 June 2009 31 Dec
2009

Equity
Share capital 36.2 36.2 36.2
Other funds 50.4 50.8 50.9
Retained earnings 239.3 118.6 156.4
Equity of the parent
company shareholders 325.9 205.5 243.4
Minority interest – – 10.8
Equity total 325.9 205.5 254.2

Non-current liabilities
Deferred tax liabilities 23.1 14.1 13.6
Pension liabilities 5.0 4.3 4.9
Provisions – 0.0 0.0
Interest-bearing non-current liabilities 116.6 0.1 0.2
Non-current liabilities total 144.8 18.5 18.8

Current liabilities
Trade payables and other current liabilities 596.0 451.9 500.5
Interest-bearing current liabilities 106.6 143.2 149.5
Current liabilities total 702.5 595.1 650.1

EQUITY AND LIABILITIES TOTAL 1173.2 819.2 923.1

819.2

923.1

Consolidated Statement
of Changes in
Equity (IFRS)
Equity of the
parent
company
Share Other Translation Retained share- Minority
EUR million capital funds differences earnings holders interest Total
Equity
1 Jan 2009 36.2 30.1 -30.1 148.2 184.4 1.0 185.5
Dividends paid – – – -11.3 -11.3 – -11.3
Share issue – 20.6 – – 20.6 – 20.6

Change in minority interest – – – – 0.0 -1.0 -1.0

Share-based payments – – – 0.1 0.1 – 0.1
Total comprehensive income
for the period under review – – -7.0 18.7 11.7 – 11.7
Equity
30 June 2009 36.2 50.8 -37.1 155.7 205.5 0.0 205.5

Equity
1 Jan 2010 36.2 50.9 -30.4 186.8 243.4 10.8 254.2
Dividends – – – -18.1 -18.1 – -18.1
Share issue – – – – 0.0 – 0.0

Change in minority interest – – – – 0.0 -10.8 -10.8

Share-based payments – – – 0.1 0.1 – 0.1
Assignment of shares – -0.1 – – -0.1 – -0.1
Total comprehensive income
for the period under review – -0.4 37.4 63.6 100.6 – 100.6
Equity
30 June 2010 36.2 50.4 7.0 232.4 325.9 0.0 325.9

232.4

325.9

0.0

325.9

Consolidated Cash Flow Statement 1 Jan – 30 June 1 Jan – 30 June 1 Jan – 31 Dec
*) (IFRS), EUR million 2010 2009 2009
Operating profit 14.2 25.9 65.4
Depreciation 5.5 4.8 9.4
Change in working capital 33.6 -24.6 37.9
Cash flow from financial
items and taxes -7.5 -8.1 -13.3
Other adjustments 8.4 -3.8 1.5
Net cash flow from operating activities 54.1 -5.8 100.9

Net cash flow from investing activities -153.3 -26.7 -28.0

Net cash flow from financing activities 108.0 28.8 14.5

Net change in cash and cash equivalents 8.9 -3.7 87.4

Cash and cash equivalents
at the beginning of the period 133.7 46.5 46.5
Foreign exchange rate differences 5.5 -0.5 -0.2
Net change in cash and cash equivalents 8.9 -3.7 87.4
Cash and cash equivalents
at the end of the period 148.1 42.2 133.7
*) Includes net cash flow of Healthcare Trade until 31 May 2010.

*) Includes net cash flow of Healthcare Trade until 31 May 2010.

Change in Property, Plant and Equipment, 1 Jan – 30 June 1 Jan – 30 June 1 Jan – 31 Dec
EUR million 2010 2009 2009
Carrying amount at the beginning of the period 53.3 54.5 54.5
Increases through acquisitions of subsidiary shares 8.9 – –
Increases 4.5 2.8 6.0
Decreases -4.0 -0.7 -1.8
Depreciation -3.7 -3.2 -6.5
Foreign exchange rate differences 2.1 -0.3 1.1
Carrying amount at the end of the period 61.0 53.1 53.3

53.1

53.3

1 Jan – 30 June 1 Jan – 30 June 1 Jan – 31 Dec
Key Figures 2010 2009 2009
Equity ratio, % 28.5% 25.8% 29.2%
Equity per share, EUR 2.16 1.36 1.61
Return on capital employed (ROCE), % 4.8% 16.1% 18.7%
Return on equity, % 5.1% 19.1% 22.1%
Net interest-bearing debt, EUR million 75.1 101.1 16.0
Gearing, % 23.0% 49.2% 6.3%
Earnings per share, EUR 0.42 0.13 0.34
Average number of shares, 1000 pcs 151 167 143 044 147 034

143 044

147 034

Derivatives, Commitments
and Contingent Liabilities

30 June 2010
Positive fair Negative fair Nominal values of
EUR million value value contracts
Derivatives recognised as
cash flow hedges
Foreign currency forward and swap contracts – – –
Interest rate swaps – -0.4 105.0
Derivatives measured at
fair value through profit or loss
Foreign currency forward and swap contracts 0.6 – 59.3

30 June 2009
Positive fair Negative fair Nominal values of
EUR million value value contracts
Derivatives recognised
as cash flow hedges
Foreign currency forward and swap contracts 2.1 – 40.8
Derivatives measured at
fair value through profit or loss
Foreign currency forward and swap contracts 0.3 – 20.0

Contingencies for Own Liabilities,
EUR million 30 June 2010 30 June 2009 31 Dec 2009
Guarantees given 119.4 35.6 36.8
Mortgages on land and buildings 2.0 2.0 2.0
Mortgages on company assets 2.2 1.9 2.0
Other guarantees and liabilities 0.1 1.4 1.9
Total 123.7 41.0 42.7

Leasing-liabilities (operating liabilities) 1.2 0.4 0.3
Rent contingencies 59.6 34.7 33.8

34.7

33.8

Net Sales by Operating Segments, 1 Jan – 30 June 1 Jan – 30 June 1 Jan – 31 Dec
EUR million 2010 2009 2009
Pharmaceutical Trade Finland 210.4 258.8 505.1
Pharmaceutical Trade Sweden 422.4 256.9 548.3
Pharmaceutical Trade Russia 255.0 213.9 480.7
Pharmaceutical Trade Baltics 15.6 17.3 35.7
Net sales to other segments -0.2 -0.3 -0.5
Continuing operations total 903.1 746.5 1569.2
Discontinued operations 65.3 69.9 145.1
Net sales to other segments -1.6 -0.6 -1.2
Group Total 966.8 815.8 1713.1

815.8

1713.1

Operating Profit by Operating Segments, 1 Jan – 30 June 1 Jan – 30 June 1 Jan – 31 Dec
EUR million 2010 2009 2009
Pharmaceutical Trade Finland 9.5 8.8 18.1
Pharmaceutical Trade Sweden 4.2 -2.3 -5.0
Pharmaceutical Trade Russia -2.5 16.3 44.5
Pharmaceutical Trade Baltics 0.4 0.4 0.9
Dental Trade 3.1 1.8 3.9
Group Administration and Others -3.5 -3.7 -5.9
Continuing operations total 11.3 21.2 56.4
Discontinued operations 56.9 4.7 8.9
Group Total 68.2 25.9 65.4

Continuing operations
Average number of personnel 4 590 4 002 3 923
Number of personnel at the end of the period 4 721 3 925 3 870

Group total
Average number of personnel 4 930 4 460 4 373
Number of personnel at the end of the period 4 721 4 399 4 299

4 399

4 299

Net Sales by Operating Segments,
EUR million Q2/2010 Q1/2010 Q4/2009 Q3/2009 Q2/2009 Q1/2009
Pharmaceutical Trade Finland 105.9 104.5 125.8 120.6 132.0 126.8
Pharmaceutical Trade Sweden 241.4 181.0 159.3 132.1 130.5 126.4
Pharmaceutical Trade Russia 132.8 122.1 148.2 118.6 106.6 107.2
Pharmaceutical Trade Baltics 7.3 8.3 10.3 8.0 8.8 8.6
Net sales to other segments -0.1 -0.1 -0.1 -0.1 -0.1 -0.2
Continuing operations total 487.3 415.7 443.5 379.2 377.8 368.8
Discontinued operations 30.9 34.4 43.4 31.9 34.9 35.0
Net sales to other segments -0.5 -1.1 -0.3 -0.3 -0.3 -0.3
Group Total 517.7 449.0 486.5 410.8 412.3 403.5

486.5

410.8

412.3

403.5

Operating Profit by Operating Segments,
EUR million Q2/2010 Q1/2010 Q4/2009 Q3/2009 Q2/2009 Q1/2009
Pharmaceutical Trade Finland 5.0 4.5 4.4 4.9 4.9 3.9
Pharmaceutical Trade Sweden 5.6 -1.4 -2.2 -0.4 -2.0 -0.4
Pharmaceutical Trade Russia -2.0 -0.4 21.6 6.6 8.6 7.6
Pharmaceutical Trade Baltics 0.2 0.3 0.3 0.2 0.2 0.1
Dental Trade 1.4 1.6 1.2 0.8 0.7 1.1
Group Administration and Others -1.9 -1.6 -0.8 -1.5 -2.0 -1.6
Continuing operations total 8.4 3.0 24.5 10.7 10.5 10.7
Discontinued operations 55.6 1.3 2.4 1.9 3.0 1.7
Group Total 64.0 4.2 26.9 12.6 13.5 12.4

26.9

12.6

13.5

12.4

1 Jan – 30 June 1 Jan – 30 June 1 Jan – 31 Dec
Net Sales by Market, EUR million 2010 2009 2009
Finland 211.5 258.5 509.9
Sweden 419.0 256.9 539.8
Russia 255.0 213.9 480.7
Baltic countries 15.6 17.3 35.7
Other countries 2.1 0.0 3.2
Continuing opertions total 903.1 746.5 1569.2

746.5

1569.2

Net Sales by Market, EUR million Q2/2010 Q1/2010 Q4/2009 Q3/2009 Q2/2009 Q1/2009
Finland 106.5 105.0 126.3 125.1 131.9 126.6
Sweden 239.5 179.4 157.7 125.2 130.5 126.4
Russia 132.8 122.1 148.2 118.6 106.6 107.2
Baltic countries 7.3 8.3 10.3 8.0 8.8 8.6
Other countries 1.2 0.9 1.0 2.2 – –
Continuing operations total 487.3 415.7 443.5 379.2 377.8 368.8

443.5

379.2

377.8

368.8

DISCONTINUED OPERATIONS

Comprehensive Income 1 Jan – 31 May 1 Jan – 31 Dec
(IFRS), EUR million 2010 2009
Discontinued operations
Net sales 65.3 145.1
Cost of goods sold -46.6 -100.3
Gross profit 18.6 44.8
Other operating income 54.2 2.2
Selling and
distribution expenses -15.0 -35.3
Administrative expenses -1.0 -2.8
Operating profit 56.9 8.9
Financial income 0.1 0.0
Financial expenses -0.1 -1.4
Profit before taxes 56.9 7.6
Income taxes*) -0.7 -2.0
Profit from the discontinued operations for the period under review 56.2 5.6

Attribution of profit from the discontinued operations
for the period under review
To parent company shareholders 56.2 5.6
To minority interest – –

-

-

Earnings per share
from the discontinued operations
Basic earnings per share, EUR 0.37 0.04
Diluted earnings per share, EUR 0.37 0.04

*) The tax expense for the period has been
calculated as the proportional share of
the total estimated taxes for the financial year.

the total estimated taxes for the financial year.

Cash Flow Statement 1 Jan – 31 May 1 Jan – 31 Dec
(IFRS), EUR million 2010 2009
Net cash flow from operating activities 6.7 -3.5
Net cash flow from investing activities -0.9 -1.9
Net cash flow from financing activities 0.2 5.4
Net change in cash and cash equivalents 6.0 -0.1

6.0

-0.1

BUSINESS COMBINATIONS DISCLOSURE

Acquisition of national pharmacy chain in Sweden (Pharmacy Company Sweden 2 AB)

Oriola-KD announced in November 2009 that it would acquire 100 per cent of the shares of
Pharmacy Company Sweden 2 AB, a national pharmacy cluster with 170 pharmacies. The
transaction was executed in February 2010. The acquired pharmacy business covers only
retail activities. The transaction does not include any contingent considerations.
Entering the pharmaceutical retail business in Sweden is an important part of
Oriola-KD’s strategy to expand the operations from pharmaceutical wholesale to retail.

The acquisition cost is calculated on the basis of the company’s provisional balance
sheet as per 19 February 2010 prepared in accordance with IFRS and the Oriola-KD Group’s
accounting principles in respect of all material elements. The provisional balance sheet
and acquisition cost calculation are unaudited.

The acquisition is accounted for using provisional values as permitted under IFRS 3R.
Over the 12 months following the acquisition, Oriola-KD will make the necessary
adjustments to these provisional values. The fair value of the identifiable fixed assets
was 8.6 million euros and inventory 22.2 million euros. These figures are provisional
figures and the values might be adjusted during 2010.

The fair value of trade receivables and other receivables is 50.9 million euros and it
does not include any material risk.

The initial purchase price allocation calculation calculated in Swedish crowns has been
translated into euros by using the exchange rate of acquisition date.

The financial result and the balance sheet of the acquired company has been consolidated
into the Oriola-KD Group from the acquisition date, i.e. 19 February 2010.

Business combinations disclosure under IFRS 3 (revised)

The 101.3 million euro goodwill arising from the acquisition is primarily representing
the strong market position, growth expectations, opportunities after monopoly
deregulation and experienced existing personnel as well as expected synergies with
Oriola-KD’s sizeable wholesale operations in Sweden. None of the goodwill is deductible
for income tax purposes.

The following table summarises the consideration paid for the pharmacy cluster and the
amounts of the assets acquired and liabilities assumed recognised at the acquisition
date, as well as the fair value at the acquisition date of the non-controlling
interest.

Consideration
19.2.2010
Carrying amount, EUR million Fair value allocations, EUR million Fair
value, EUR
million
Cash 161.5 0.0 161.5
Equity instruments 0 0.0 0.0
Contingent consideration 0 0.0 0.0
Total consideration transferred 161.5 161.5
Indemnification asset 0 0.0 0.0
Fair value of equity interest held before 0 0.0 0.0
the business combination
Total consideration 161.5 161.5

Acquisition related costs
-included in administrative expenses in the consolidated income statement for 2009 1.2
-included in administrative expenses in the consolidated income statement for 2010 0.5

Recognised amounts of identifiable
assets acquired and liabilities assumed
Cash and cash equivalents 2.4 0.0 2.4
Property, plant and equipment 8.6 0.0 8.6
Trademarks (included in intangibles) 0.0 0.0 0.0
Pharmacy licences and rental agreements (included in intangibles) 0.0 25.4 25.4
Contractual customer relationship (included in intangibles) 0.0 0.0 0.0
Investment in associates 0.0 0.0 0.0
Available-for-sale financial assets 0.0 0.0 0.0
Inventories 22.2 0.2 22.4
Trade receivables 44.0 0.0 44.0
Other receivables 6.8 0.0 6.8
Trade and other payables -42.8 0.0 -42.8
Retirement benefit obligations 0.0 0.0 0.0
Borrowings 0.0 0.0 0.0
Contingent liability 0.0 0.0 0.0
Deferred tax liabilities 0.0 -6.7 -6.7
Total identifiable net assets 41.3 18.9 60.2
Non-controlling interest 0.0 0.0 0.0
Goodwill 101.3

The pro forma net sales of the acquired pharmacy cluster was SEK 4.6 billion and pro
forma operating profit including average central overhead costs of Apoteket AB was SEK
205 million.

Espoo 28 July 2010

Oriola-KD Corporation’s Board of Directors

Oriola-KD Corporation

Eero Hautaniemi
President and CEO

Kimmo Virtanen
Executive Vice President and CFO

Further information:

Eero Hautaniemi
President and CEO
tel. +358 (0)10 429 2109
e-mail: eero.hautaniemi@oriola-kd.com

Kimmo Virtanen
Executive Vice President and CFO
tel. +358 (0)10 429 2069
e-mail: kimmo.virtanen@oriola-kd.com

Pellervo Hämäläinen
Vice President, Communications and Investor Relations
tel. +358 (0)10 429 2497
e-mail: pellervo.hamalainen@oriola-kd.com

Distribution
NASDAQ OMX Helsinki Ltd
Principal media

Published by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo, Finland
www.oriola-kd.com

HUG#1434559

Oriola-KD Corporation’s Interim Report for 1 January – 30 June 2010

http://hugin.info/136732/R/1434559/380121.pdf